21:43 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

Emixustat: Ph IIa started

Kubota’s Acucela Inc. subsidiary began a blinded, U.S. Phase IIa trial to evaluate 2.5, 5 and 10 mg oral emixustat once daily for 1 month in about 30 patients. Kubota Pharmaceutical Holdings Co. Ltd. (Tokyo:4596), Tokyo,...
21:31 , Dec 16, 2016 |  BC Week In Review  |  Company News

Kubota, EyeMedics deal

EyeMedics and Kubota's Acucela Inc. subsidiary partnered to develop lipoxin biomimetic small molecules to treat, prevent and diagnose ophthalmic diseases, with an initial focus on diabetic macular edema (DME). EyeMedics will be responsible for preclinical...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Company News

Otsuka Pharmaceutical, Acucela deal

Otsuka terminated deals with Acucela to co-develop and co-commercialize Acucela’s emixustat ( ACU-4429) and Otsuka’s OPA-6566. The emixustat deal was signed in 2008 and granted Otsuka co-development rights in North America and exclusive rights...
00:23 , Jun 15, 2016 |  BC Extra  |  Company News

Acucela slides after Otsuka ends ophthalmic deals

Acucela Inc. (Tokyo:4589) sank Y400 (24%) to Y1,253 on Tuesday after it said Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) terminated co-development deals for Acucela's emixustat (formerly ACU-4429) and Otsuka's OPA-6566. Last month, Acucela said emixustat...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Emixustat: Phase IIb/III data

Top-line data from the double-blind, U.S. Phase IIb/III S.E.A.T.T.L.E. trial in 508 patients with GA secondary to dry age-related AMD showed that once-daily 2.5, 5 and 10 mg oral emixustat each missed the primary endpoint...
00:56 , May 27, 2016 |  BC Extra  |  Clinical News

Acucela's emixustat fails in AMD study

Acucela Inc. (Tokyo:4589) dropped Y1,000 (17%) to Y4,790 after it said emixustat (formerly ACU-4429) missed the primary endpoint of the Phase IIb/III S.E.A.T.T.L.E. study to treat geographic atrophy (GA) in patients with age-related macular degeneration....
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

Emixustat: Phase II started

Acucela began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate once-daily oral emixustat for 12 weeks in 20 patients. Doses of emixustat will be doubled each week until week 4, after which patients will...
07:00 , May 2, 2016 |  BioCentury  |  Finance

Rational retail in Japan

The 2012 Japanese biotech bubble was fueled by irrational retail exuberance over a Nobel Prize awarded to a stem cell academic, but retail investors now are largely rewarding companies based on news events or upcoming...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

None shall pass

Biotech recorded its worst quarter in about 14 years, and no market cap bands were spared from the carnage. Big caps, normally a safe haven during turbulent markets, shed 16.1% and had only three of...